Molecules for administration to ROS1 mutant cancer cells
US10231965B2 · kind B2 · utility
7Cited by
4References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 17, 2015 |
| Grant date | Mar 19, 2019 |
| Priority date | — |
| Expiry date | Feb 17, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.